Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.

Autor: Afari J; Berenson Cancer Center, West Hollywood, CA; Sackler School of Medicine, Tel Aviv, Israel., Spektor TM; Oncotherapeutics, West Hollywood, CA., Turner C; Oncotherapeutics, West Hollywood, CA., Cohen A; Oncotherapeutics, West Hollywood, CA., Bessudo A; California Cancer Associates for Research and Excellence (cCARE), Encinitas, CA., Jhangiani H; Compassionate Oncology Medical Group, Los Angeles, CA, USA., Gabrail N; Gabrail Cancer Center, Canton, OH., Kubba S; Inland Hematology Oncology Medical Group, Inc., San Bernardino, CA., Neidhart JD; San Juan Oncology Associates, Farmington, NM., Eshaghian S; Compassionate Oncology Medical Group, Los Angeles, CA, USA., Swift RA; Berenson Cancer Center, West Hollywood, CA., Eades BM; Berenson Cancer Center, West Hollywood, CA., Kim C; Oncotherapeutics, West Hollywood, CA., Kim S; Oncotherapeutics, West Hollywood, CA., Vescio R; Cedars-Sinai Medical Center, Los Angeles, CA., Berenson JR; Berenson Cancer Center, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address: jberenson@berensoncancercenter.com.
Jazyk: angličtina
Zdroj: Experimental hematology [Exp Hematol] 2022 Oct; Vol. 114, pp. 54-60. Date of Electronic Publication: 2022 Aug 04.
DOI: 10.1016/j.exphem.2022.07.303
Abstrakt: Competing Interests: Conflict of Interest Disclosure James R. Berenson received consultant fees, speakers’ bureau honoraria, and research funding from Bristol Myers Squibb.
Databáze: MEDLINE
Externí odkaz: